CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment

Autor: Audrey Abecassis, Nathalie Roders, Maxime Fayon, Caroline Choisy, Elisabeth Nelson, Stephanie Harel, Bruno Royer, Camille Villesuzanne, Alexis Talbot, David Garrick, Michele Goodhardt, Jean‐Paul Fermand, Mike Burbridge, Bertrand Arnulf, Jean‐Christophe Bories

Publikováno v: eJHaem, Vol 3, Iss 3, Pp 970-974 (2022)

Abstract Chimeric antigen receptor T cells (CAR‐T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from M

Externí odkaz: https://doaj.org/article/338bcbe39cad4692acdfb83db0d67b2b

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma

Autor: Maxime Fayon, Carolina Martinez-Cingolani, Audrey Abecassis, Nathalie Roders, Elisabeth Nelson, Caroline Choisy, Alexis Talbot, Armand Bensussan, Jean-Paul Fermand, Bertrand Arnulf, Jean-Christophe Bories

Publikováno v: Haematologica, Vol 106, Iss 4 (2020)

Externí odkaz: https://doaj.org/article/ab64dca534a844b489b55ce6a30ed6df

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo

Autor: Camille Bono, Lionel Karlin, Stephanie Harel, Enguerran Mouly, Sylvaine Labaume, Lionel Galicier, Sébastien Apcher, Hélène Sauvageon, Jean-Paul Fermand, Jean-Christophe Bories, Bertrand Arnulf

Publikováno v: Haematologica, Vol 97, Iss 7 (2012)

Background Multiple myeloma is characterized by the accumulation of tumor plasma cells in the bone marrow. Despite therapeutic improvements brought by proteasome inhibitors such as bortezomib, myeloma remains an incurable disease. In a variety of hum

Externí odkaz: https://doaj.org/article/dd25403000664a2aa12a713a00a63071

CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas

Autor: Van Anh Ta, Maxime Battistella, Lin Pierre Zhao, Gabor Dobos, Caroline Ram-Wolff, Isabelle Madelaine, Jean-Christophe Bories, Olivier Tournilhac, Jacques Rouanet, Richard Veyrat-Masson, Jean-David Bouaziz, Anne Marie-Cardine, Martine Bagot, Armand Bensussan, Hélène Moins-Teisserenc, Adèle De Masson

Publikováno v: Journal of Investigative Dermatology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::241d7212042d5130576dd17d2c557cd5
https://doi.org/10.1016/j.jid.2023.01.009

Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients

Autor: Rim Trad, Rafik Haderbache, Pauline Varlet, Paul-Oliver Rouzaire, Catherine Thieblemeont, Christophe Ferrand, Ibrahim Yakoub Agha, Emmanuel Bachy, Sophie Caillat-Zucman, Eric Hervouet, Vincent Allain, Pierre Sujobert, Clementine Nicod, Fabienne Venet, Denis Caillot, Mathieu Neto Da Rocha, Xavier Roussel, Walid Warda, Lucie Bouquet, Jean Christophe Bories, Olivier Casasnovas, Nicolas Boissel, Melanie Guiot, Marina Deschamps

Publikováno v: Journal of Translational Medicine
Journal of Translational Medicine, BioMed Central, 2021, 19 (1), ⟨10.1186/s12967-021-02925-z⟩
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-13 (2021)

Background Genetically engineered chimeric antigen receptor (CAR) T lymphocytes are promising therapeutic tools for cancer. Four CAR T cell drugs, including tisagenlecleucel (tisa-cel) and axicabtagene-ciloleucel (axi-cel), all targeting CD19, are cu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65be9e1b3274277f61c8bb5dcc5a792a
https://hal.uca.fr/hal-03443941